These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16048265)

  • 21. Novel cardiovascular risk factors in end-stage renal disease.
    Zoccali C; Mallamaci F; Tripepi G
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S77-80. PubMed ID: 14684678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ischemia-modified albumin, a predictive marker of major adverse cardiovascular events in continuous ambulatory peritoneal dialysis patients.
    Su X; Zhang K; Guo F; Yuan B; Wang C; Xiao L; Wang J; Huang H
    Clin Biochem; 2013 Oct; 46(15):1410-3. PubMed ID: 23796881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease.
    Zoccali C
    Blood Purif; 2002; 20(5):469-72. PubMed ID: 12207095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevated plasma levels of PAI-1 predict cardiovascular events and cardiovascular mortality in prevalent peritoneal dialysis patients.
    Arikan H; Koc M; Tuglular S; Ozener C; Akoglu E
    Ren Fail; 2009; 31(6):438-45. PubMed ID: 19839820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma concentration of coupling factor 6 and cardiovascular events in patients with end-stage renal disease.
    Osanai T; Nakamura M; Sasaki S; Tomita H; Saitoh M; Osawa H; Yamabe H; Murakami S; Magota K; Okumura K
    Kidney Int; 2003 Dec; 64(6):2291-7. PubMed ID: 14633154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients.
    Helal I; Smaoui W; Hamida FB; Ouniss M; Aderrahim E; Hedri H; Elyounsi F; Maiz HB; Abdallah TB; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):59-62. PubMed ID: 20061694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
    Kielstein JT; Zoccali C
    Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach.
    Ravani P; Tripepi G; Malberti F; Testa S; Mallamaci F; Zoccali C
    J Am Soc Nephrol; 2005 Aug; 16(8):2449-55. PubMed ID: 15944335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of arterial stiffness on adverse cardiovascular outcomes and mortality in peritoneal dialysis patients.
    Sipahioglu MH; Kucuk H; Unal A; Kaya MG; Oguz F; Tokgoz B; Oymak O; Utas C
    Perit Dial Int; 2012; 32(1):73-80. PubMed ID: 21454392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemodialysis hypotension: interaction of inhibitors, iNOS, and the interdialytic period.
    Kang ES; Tevlin MT; Wang YB; Chiang TM; Cardenas R; Myers LK; Acchiardo SR
    Am J Med Sci; 1999 Jan; 317(1):9-21. PubMed ID: 9892267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
    van Guldener C; Nanayakkara PW; Stehouwer CD
    Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kidney disease as an independent risk factor for cardiovascular events.
    Kumar J; Shah SV
    J Ren Nutr; 2005 Jan; 15(1):99-104. PubMed ID: 15648016
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels.
    Borazan A; Aydemir S; Sert M; Yilmaz A
    Mediators Inflamm; 2004 Dec; 13(5-6):361-4. PubMed ID: 15770053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypervolemia, hypoalbuminemia and mitral calcification as markers of cardiovascular risk in peritoneal dialysis patients.
    Querido S; Quadros Branco P; Silva Sousa H; Adragão T; Araújo Gonçalves P; Gaspar MA; Barata JD
    Rev Port Cardiol; 2017 Sep; 36(9):599-604. PubMed ID: 28843932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma reduced homocysteine and other aminothiol concentrations in patients with CKD.
    Sjöberg B; Anderstam B; Suliman M; Alvestrand A
    Am J Kidney Dis; 2006 Jan; 47(1):60-71. PubMed ID: 16377386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
    Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
    Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peritoneal dialysis and cardiovascular disease.
    Balafa O; Krediet RT
    Minerva Urol Nefrol; 2012 Sep; 64(3):153-62. PubMed ID: 22971680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between depression symptoms with inflammation and cardiovascular risk factors in patients undergoing peritoneal dialysis.
    Ko GJ; Kim MG; Yu YM; Jo SK; Cho WY; Kim HK
    Nephron Clin Pract; 2010; 116(1):c29-35. PubMed ID: 20460938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperhomocysteinemia and its relationship to cardiovascular disease in ESRD: influence of hypoalbuminemia, malnutrition, inflammation, and diabetes mellitus.
    Suliman ME; Stenvinkel P; Bárány P; Heimbürger O; Anderstam B; Lindholm B
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S89-95. PubMed ID: 12612961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cardiovascular morbidity and mortality risk factors in peritoneal dialysis patients].
    Jovanović DB
    Srp Arh Celok Lek; 2008; 136(5-6):313-8. PubMed ID: 18792634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.